Cost-effectiveness of couples' voluntary HIV counselling and testing in six African countries: a modelling study guided by an HIV prevention cascade framework.
Africa
HIV
HIV prevention cascade
cost-effectiveness
costs and cost analysis
couples
prevention and control
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
17
10
2019
revised:
17
03
2020
accepted:
23
04
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
24
4
2021
Statut:
ppublish
Résumé
Couples' voluntary HIV counselling and testing (CVCT) is a high-impact HIV prevention intervention in Rwanda and Zambia. Our objective was to model the cost-per-HIV infection averted by CVCT in six African countries guided by an HIV prevention cascade framework. The HIV prevention cascade as yet to be applied to evaluating CVCT effectiveness or cost-effectiveness. We defined a priority population for CVCT in Africa as heterosexual adults in stable couples. Based on our previous experience nationalizing CVCT in Rwanda and scaling-up CVCT in 73 clinics in Zambia, we estimated HIV prevention cascade domains of motivation for use, access and effectiveness of CVCT as model parameters. Costs-per-couple tested were also estimated based on our previous studies. We used these parameters as well as country-specific inputs to model the impact of CVCT over a five-year time horizon in a previously developed and tested deterministic compartmental model. We consider six countries across Africa with varied HIV epidemics (South Africa, Zimbabwe, Kenya, Tanzania, Ivory Coast and Sierra Leone). Outcomes of interest were the proportion of HIV infections averted by CVCT, nationwide CVCT implementation costs and costs-per-HIV infection averted by CVCT. We applied 3%/year discounting to costs and outcomes. Univariate and Monte Carlo multivariate sensitivity analyses were conducted. We estimated that CVCT could avert between 54% (Sierra Leone) and 62% (South Africa) of adult HIV infections. Average costs-per-HIV infection averted were lowest in Zimbabwe ($550) and highest in South Africa ($1272). Nationwide implementations would cost between 7% (Kenya) and 21% (Ivory Coast) of a country's President's Emergency Plan for AIDS Relief (PEPFAR) budget over five years. In sensitivity analyses, model outputs were most sensitive to estimates of cost-per-couple tested; the proportion of adults in heterosexual couples and HIV prevention cascade domains of CVCT motivation and access. Our model indicates that nationalized CVCT could prevent over half of adult HIV infections for 7% to 21% of the modelled countries' five-year PEPFAR budgets. While other studies have indicated that CVCT motivation is high given locally relevant promotional and educational efforts, without required indicators, targets and dedicated budgets, access remains low.
Identifiants
pubmed: 32602618
doi: 10.1002/jia2.25522
pmc: PMC7325504
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25522Subventions
Organisme : NIH HHS
ID : R01 MH66767
Pays : United States
Organisme : NIH HHS
ID : R01 HD40125
Pays : United States
Organisme : NIH HHS
ID : R01 MH95503
Pays : United States
Organisme : NIH HHS
ID : K01 MH107320
Pays : United States
Organisme : NIH HHS
ID : R01 AI051231
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW001042
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Sex Transm Infect. 2017 Jun;93(4):259-266
pubmed: 28082662
J Acquir Immune Defic Syndr. 2014 May 1;66(1):e1-7
pubmed: 24326600
BMC Int Health Hum Rights. 2014 Dec 24;14:39
pubmed: 25539670
BMJ. 1992 Jun 20;304(6842):1605-9
pubmed: 1628088
BMC Public Health. 2015 Jul 02;15:601
pubmed: 26136116
Lancet. 2018 May 5;391(10132):1799-1829
pubmed: 29678342
AIDS. 1995 Jul;9(7):745-50
pubmed: 7546420
JAMA. 1992 Dec 16;268(23):3338-43
pubmed: 1453526
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25309
pubmed: 31328375
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
AIDS Behav. 2016 Sep;20(9):2090-100
pubmed: 26906021
BMC Public Health. 2014 Dec 20;14:1309
pubmed: 25526799
Int J Infect Dis. 2018 Jan;66:131-134
pubmed: 29129712
Contemp Clin Trials. 2018 Aug;71:63-69
pubmed: 29879469
AIDS Care. 2011 Aug;23(8):998-1005
pubmed: 21390889
Lancet HIV. 2019 Jan 1;6(1):e60-e66
pubmed: 32066995
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e51-e58
pubmed: 27741033
J Acquir Immune Defic Syndr. 2006 Sep;43(1):91-5
pubmed: 16885775
Bull World Health Organ. 2016 Dec 1;94(12):925-930
pubmed: 27994285
AIDS. 2003 Mar 28;17(5):733-40
pubmed: 12646797
AIDS. 2012 Jan 14;26(2):217-27
pubmed: 22008653
AIDS Behav. 2009 Jun;13 Suppl 1:92-102
pubmed: 19308720
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25311
pubmed: 31328436
BMJ Open. 2012 Sep 06;2(5):
pubmed: 22956641
South Afr J HIV Med. 2017 Nov 29;18(1):691
pubmed: 29568627
BMC Public Health. 2016 Aug 08;16:744
pubmed: 27502690
PLoS One. 2017 Oct 16;12(10):e0185142
pubmed: 29036208
J Int AIDS Soc. 2016 Dec 12;19(1):21134
pubmed: 27964776
Reprod Health Matters. 2008 Nov;16(32):151-61
pubmed: 19027631
J Int AIDS Soc. 2014 Feb 21;17:18765
pubmed: 24560339
AIDS Behav. 2013 May;17 Suppl 1:S43-50
pubmed: 22961498
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):123-131
pubmed: 28737591
AIDS Behav. 2010 Jun;14(3):558-66
pubmed: 19763813
BMC Public Health. 2012 Sep 18;12:801
pubmed: 22984868
AIDS Behav. 2019 May;23(5):1095-1103
pubmed: 30737610
J Acquir Immune Defic Syndr. 2002 May 1;30(1):73-80
pubmed: 12048366
Open AIDS J. 2016 Feb 26;10:1-13
pubmed: 27014393
Int J Epidemiol. 2019 Feb 1;48(1):217-227
pubmed: 30358840
Int J STD AIDS. 2001 Mar;12(3):181-8
pubmed: 11231872
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
EClinicalMedicine. 2019 May 20;10:10-31
pubmed: 31193863
Epidemiology. 2016 Jan;27(1):91-7
pubmed: 26484424
PLoS One. 2015 Jan 20;10(1):e0116100
pubmed: 25602351
AIDS. 1997 Sep;11 Suppl 1:S103-10
pubmed: 9376093
JAMA. 1996 Oct 16;276(15):1253-8
pubmed: 8849754
BMC Public Health. 2009 Nov 18;9 Suppl 1:S5
pubmed: 19922689
Lancet Glob Health. 2017 Sep;5(9):e907-e915
pubmed: 28807189
AIDS. 2005 Mar 24;19(6):603-9
pubmed: 15802979
Epidemics. 2014 Mar;6:1-9
pubmed: 24593916
Niger Med J. 2014 Jul;55(4):294-8
pubmed: 25114363
Soc Sci Med. 2001 Dec;53(11):1397-411
pubmed: 11710416
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):91-100
pubmed: 26715490
AIDS Care. 2012;24(4):413-9
pubmed: 21939369
AIDS. 1999 Jun 18;13(9):1083-9
pubmed: 10397539
Int J Technol Assess Health Care. 2013 Apr;29(2):117-22
pubmed: 23587340
Int J STD AIDS. 2008 Jun;19(6):406-9
pubmed: 18595879
BMC Infect Dis. 2016 Aug 08;16:379
pubmed: 27502776
Cult Health Sex. 2018 Jun;20(6):625-639
pubmed: 28903628
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S167-73
pubmed: 27355505
N Engl J Med. 2019 Jul 18;381(3):286-288
pubmed: 31314975
AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):901-10
pubmed: 11461676
PLoS One. 2015 Apr 20;10(4):e0124548
pubmed: 25894583
AIDS Care. 2016;28 Suppl 3:59-66
pubmed: 27421052
Lancet HIV. 2015 Nov;2(11):e483-91
pubmed: 26520928
J Int Assoc Provid AIDS Care. 2014 Mar-Apr;13(2):135-44
pubmed: 23995295